Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile

BACKGROUND: Targeted agents, such as antiangiogenic drugs (e.g., bevacizumab) and poly(ADP-ribose) polymerase inhibitors (e.g., rucaparib), have been shown to improve outcomes in patients with newly diagnosed or recurrent ovarian cancer. Evidence suggests that combinations of these two classes of ta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Target Oncol
Main Authors: Lorusso, Domenica, Maltese, Giuseppa, Sabatucci, Ilaria, Cresta, Sara, Matteo, Cristina, Ceruti, Tommaso, D’Incalci, Maurizio, Zucchetti, Massimo, Raspagliesi, Francesco, Sonetto, Cristina, Sinno, Valentina, Ronzulli, Dominique, Giolitto, Serena, de Braud, Filippo
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2020
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7810645/
https://ncbi.nlm.nih.gov/pubmed/33369704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-020-00780-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados